StockTipsArenaBeta

BUY Piramal Pharma Limited — ICICI Securities

BUYPiramal Pharma Limited

byICICI SecuritiesHorizon: NA (inferred 1 year)30 Jan 2026via Institutional / Brokerage Research

Entry₹154.68Inferred
Target₹230
Total upside +48.69%
Stop lossNot given
CMP₹214.222d ago
Active+38.49%+7.37%upside left 5 mo left
Follow ICICI Securities for new calls(68% target hit, 1020 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 6 other Long-term calls on PPLPHARMA

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 3:23 am IST
18 supporting10 neutral6 opposing
Supports the BUY call (18)

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 1w ago

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

NewsGoogle News·26 Aug · 2w ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · 2w ago

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)

Yapan Bio to become Piramal subsidiary following acquisition

NewsGoogle News·20 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (10)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 1w ago

(opens in new tab)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 1w ago

(opens in new tab)

Piramal Pharma emphasises sustainability in FY 2025-26 report

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)

Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore

NewsCnbc-Tv18·13 Aug · 3w ago

(opens in new tab)
Weighs against the BUY call (6)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·4 Sept · 2d ago

Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)

Piramal Pharma block deal likely cancelled; stock falls 3%

NewsCnbc-Tv18·14 Aug · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.